不同剂量米非司酮治疗围绝经期功血临床观察

目的观察及比较不同剂量米非司酮在围绝经期功血中的临床效果。方法回顾性分析本院2011年7月～2012年12月治疗的84例绝经期功血患者，将其中42例口服米非司酮5．0mg者归为A组，42例口服米非司酮10．0mg者归为B组，然后将两组患者的治疗总有效率、复发率、不良反应发生率及治疗前后的子宫内膜厚度、血清性激素水平进行比较。结果B组治疗后1个月及3个月的总有效率均高于A组，复发率则低于A组，子宫内膜厚度低于A组，血清性激素水平也优于A组，均有显著性差异（P〈0．05），而两组的不良反应发生率则无显著性差异（P〉0．05）。结论米非司酮10．0mg治疗围绝经期功血的综合疗效相对更好，且安全性也值得肯定。

Clinical observation of different dosages of mifepristone in the treatment of perimenopausal dysfunctional uterine bleeding

Objective To observe and compare the clinical effect of different dosages of mifepristone in the treatment of perimenopausal dysfunctional uterine bleeding. Methods 84 patients with perimenopausal dysfunctional uterine bleeding who were admitted and treated in our hospital from July 2011 to December 2012 were analyzed retrospectively. 42 patients were assigned to a group A, which was orally given 5.0 mg of mifepristone. Another 42 patients were assigned to a group B, which was orally given 10.0 mg of mifepristone. Total effective rate, relapse rate, incidence of adverse events, thickness of endometrium before and after the treatment, and levels of serum sex hormone in the two groups were compared. Results The total effective rates one month and three months after the treatment in the group B were both higher than those in the group A, and the relapse rate was lower than that in the group A. The thickness of endometrium in the group B was lower than that in the group A, and the level of serum sex hormone was also better than that in the group A. All the differences were statistically significant （P 〈 0.05）; the incidence of adverse events in the two groups were not significantly different （P 〉 0.05）. Conclusion 10.0 mg of mifepristone in the treatment of perimenopausal dysfunctional uterine bleeding has a better comprehensive curative effect and its safety can be assured.